Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Candriam Equities L Biotechnology

+ Add to Watchlist

DEXEBTD:LX

550.75 USD 1.78 0.32%

As of 00:59:30 ET on 02/26/2015.

Snapshot for Candriam Equities L Biotechnology (DEXEBTD)

Year To Date: +10.30% 3-Month: +11.03% 3-Year: +41.42% 52-Week Range: 347.68 - 550.75
1-Month: +3.69% 1-Year: +26.19% 5-Year: +30.03% Beta vs BTK: 0.94

Mutual Fund Chart for DEXEBTD

No chart data available.
  • DEXEBTD:LX 550.75
  • 1M
  • 1Y
Interactive DEXEBTD Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DEXEBTD

Candriam Equities L - Biotechnology is a SICAV incorporated under the laws of Luxembourg. The Fund's objective is capital appreciation. The Fund invests in global biotechnology stocks. Because the sector is currently experiencing the highest growth in the U.S., at least two-thirds of the Fund's assets will be invested in U.S. biotechnology stocks.

Inception Date: 04-06-2000 Telephone: 352-254-3431
Managers: RUDI VAN DEN EYNDE
Web Site: www.candriam.com

Fundamentals for DEXEBTD

NAV (on 2015-02-26) 550.75
Assets (M) (on 2015-02-26) 844.40
Fund Leveraged N
Minimum Investment -
Minimum Subsequent Investment -

Dividends for DEXEBTD

Dividend Type Income
Dividend Frequency Annual
Last Dividend Net (on 2014-04-29) 0.60
Dividend Yield (ttm) 0.13

Fees & Expenses for DEXEBTD

Front Load 3.50
Back Load 0.00
Current Mgmt Fee 1.50
Redemption Fee 0.00
12b1 Fee -
Expense Ratio 1.81

Top Fund Holdings for DEXEBTD

Filing Date: 01/30/2015
Name Position Value % of Total
Biogen Idec Inc 163,000 63,433,080 8.143%
Celgene Corp 520,000 61,963,200 7.954%
Gilead Sciences Inc 526,000 55,140,580 7.078%
Amgen Inc 333,000 50,702,580 6.509%
Regeneron Pharmaceuticals Inc 78,000 32,499,480 4.172%
Alexion Pharmaceuticals Inc 168,000 30,784,320 3.952%
Vertex Pharmaceuticals Inc 204,000 22,468,560 2.884%
Illumina Inc 95,000 18,543,050 2.380%
Incyte Corp 214,000 17,057,940 2.190%
BioMarin Pharmaceutical Inc 174,000 16,905,840 2.170%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil